Leonard joins MonoSol Rx with 25 years of industry experience
Warren, N.J., – December 1, 2015 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and address unmet needs, today announced that the Company has appointed Joanne M. Leonard as Chief Financial Officer.
Ms. Leonard brings 25 years of extensive finance and operational experience as a COO/CFO working with emerging public and private biotechnology and specialty pharmaceuticals companies. During her career she has completed numerous equity and debt transactions including an initial public stock offering, and strategic partnerships with global pharmaceutical companies generating over $1 billion in financing and partnership cash.
Ms. Leonard joins MonoSol Rx from a life sciences venture capital firm where for four years she served as COO/CFO of several portfolio companies successfully raising capital and restructuring operations and identifying and analyzing strategic opportunities. Ms. Leonard was previously COO of Epigenesis Pharmaceuticals where she also served as CFO and Treasurer for nine years. At Epigenesis, Ms. Leonard successfully executed a corporate restructuring and the company's first private placement with venture capital and private equity investors and was recognized as a finalist for the N.J. Technology Counsel CFO Deal of the Year Award. She was instrumental in advancing Epigenesis' inhaled respiratory products through Phase II clinical development and led the sale of company assets. Prior to joining Epigenesis, Ms. Leonard was CFO and Treasurer of Memory Pharmaceuticals and of V.I. Technologies, which were both sold to global pharmaceutical companies. Early in her career, she was employed eight years with KPMG and is a Certified Public Accountant.
"I am excited to join the MonoSol Rx team and to have the opportunity to further MonoSol Rx's reach in the financial markets, especially with the Company's ongoing drug partnership and capital raise initiatives," Joanne commented. "It is my goal to leverage my expertise in the pharmaceutical and healthcare financial sectors to help MonoSol Rx further align itself as an innovator in drug delivery technology."
Keith Kendall, CEO of MonoSol Rx said, "We are pleased to have Joanne on our team. Her experience with financing and building emerging companies is particularly valuable as we seek to expand our product pipeline. With her knowledge and relationships in the healthcare financial space coupled with her impressive accomplishments in the life sciences sector, we at MonoSol Rx are confident Ms. Leonard will play an instrumental role in our Company's continued success."
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.